Skip to content. | Skip to navigation

News
>
Article l Success in early parenteral development

Article l Success in early parenteral development

Medium: Pharmaceutical Outsourcing
Author: Dr. Claus Feussner, Senior Vice President, Vetter Development Service

How do you choose the right Contract Development and Manufacturing Organization (CDMO)? What are the benefits for a small biotech in working with a CDMO? Are there also equal benefits in partnerships for large bio/pharmaceutical companies after in-licensing a compound or the outright acquisition of a smaller company?

The cost of bringing a drug from the earliest clinical phases through to manufacturing and eventually, on into the market is a high risk venture for any company but especially so for the smaller biotech company with limited resources. This is why many choose to work with one or more trusted partners and focus their efforts on their key strengths like drug discovery. There are a variety of benefits in utilizing the services of a trusted CDMO. Positive cooperation with one or more partners is a good way to increase the potential for successful drug development. Even following the acquisition of a drug candidate or the smaller company itself, large pharmaceutical companies will still benefit from this type of cooperation. Learn more about how to choose the right partner and the many benefits of working with a trusted CDMO. In this Pharmaceutical Outsourcing article, Dr. Claus Feussner, Senior Vice President Vetter development Service, offers his insight and expertise on this issue and offers advice on how to avoid the pitfalls of early parenteral drug development.

Article
For a small biotech company, the path of success in early parenteral development can be especially perilous.

Back to newsroom